

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

E. BLUM & CO.  
Vorderberg 11  
CH-8044 Zürich  
SUISSE

30. AUG. 2004						<input checked="" type="checkbox"/>	N	A
LPA	NF	MR	WV	BH	A		K	
2		1						

*30.8.04*

PCT

## NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year)

26.08.2004

Applicant's or agent's file reference  
06259PC

### IMPORTANT NOTIFICATION

International application No.  
PCT/B 03/01257

International filing date (day/month/year)  
28.03.2003

Priority date (day/month/year)  
28.03.2002

Applicant  
THE GENETICS COMPANY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international  
preliminary examining authority:



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized Officer

Rauf, A



Tel. +49 89 2399-7548



# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Article 36 and Rule 70)

Applicant's or agent's file reference 06259PC	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/B 03/01257	International filing date ( <i>day/month/year</i> ) 28.03.2003	Priority date ( <i>day/month/year</i> ) 28.03.2002
International Patent Classification (IPC) or both national classification and IPC C12N15/11		
Applicant THE GENETICS COMPANY et al.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 3 sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the opinion</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input checked="" type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input type="checkbox"/> Certain observations on the international application</li> </ul>		
Date of submission of the demand  24.10.2003	Date of completion of this report  26.08.2004	
Name and mailing address of the international preliminary examining authority:   <div style="margin-left: 20px;"> European Patent Office  D-80298 Munich  Tel. +49 89 2399 - 0 Tx: 523656 epmu d  Fax: +49 89 2399 - 4465 </div>	Authorized Officer  Barnas, C  Telephone No. +49 89 2399-7469  	

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/IB 03/01257**

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, Pages**

1-42 as originally filed

**Sequence listings part of the description, Pages**

1-14 as originally filed

**Claims, Numbers**

1-25 received on 02.06.2004 with letter of 02.06.2004

**Drawings, Sheets**

1-6 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.  
☒ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/IB 03/01257

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 15, 20, 22

because:

☒ the said international application, or the said claims Nos. 15, 20, 22 relate to the following subject matter which does not require an international preliminary examination (specify):

**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

**IV. Lack of unity of invention**

1. In response to the invitation to restrict or pay additional fees, the applicant has:

☐ restricted the claims.

☐ paid additional fees.

☐ paid additional fees under protest.

☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/IB 03/01257

☐ complied with.

☒ not complied with for the following reasons:

**see separate sheet**

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

☒ all parts.

☐ the parts relating to claims Nos. .

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes: Claims	1-25
	No: Claims	
Inventive step (IS)	Yes: Claims	1-21
	No: Claims	22-25
Industrial applicability (IA)	Yes: Claims	1-14, 16-19, 21, 23-25
	No: Claims	

**2. Citations and explanations**

**see separate sheet**

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claims 15, 20, 22 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

For the assessment of said claims on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Re Item IV**

**Lack of unity of invention**

The present application contains two separate groups of inventions that are not so linked as to form a single general inventive concept. The two inventions are:

1. An isolated protein as described in claim 1 and associated subject matter and methods involving the nucleic acid SEQ ID NO: 1, and the protein SEQ ID NO: 2 as described in claims 2-5, 9, 13 (complete); 10-12, 15-19 (part).
2. Methods involving an ELP protein as described in claims 6-8, 14, 20-25 (complete); 10-12, 15-19 (part).

The common concept linking together the two groups of inventions is a protein. Since proteins are known the above listed separate groups of inventions are not so linked as to form a single general inventive concept and the present application, therefore, lacks unity (Rule 13.1 PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/IB 03/01257

**Re Item V**

**Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

The documents mentioned in the present Written Opinion / International Preliminary Examination Report are numbered as in the International Search Report. D1 corresponds to the first document of the Search Report, D2 to the second document etc.

The document/s/ D8 was/were not cited in the international search report. A copy/Copies of the document/s/ is/are appended hereto.

D8: Eichenmuller et al: 'The human EMAP-like protein-70 (ELP70) is a microtubule destabilizer that localizes to the mitotic apparatus' Journal of Biological Chemistry, vol. 277. no. 2, January 11, 2002, pages 1301-1309

1. The term "ELP protein" or "human ELP protein" as used in claims 6, 8, 14-16, 20, 22, 25 embraces the human ELP protein disclosed in D8. The subject matter of claims 22-25 would be provided by the skilled person, according to the circumstances, using routine procedures starting from D8 without the exercise of inventive skill. **Claims 22-25** are, therefore, not inventive.
2. D2 represents the closest prior art for group 1 of inventions. Said document discloses the nucleotide sequence and protein sequence of a new member (epsin 4) of the epsin family. The difference to the subject matter of claims 1-5, 9 and 13 is the isolation of an additional protein encoded by said nucleic acid and its use for diagnostic purpose. The cited prior art does not contain any indication that would prompt the skilled person to use the gene of D2 for such purposes. Said claims, are, therefore inventive.
3. D8 represents the closest prior art for group 2 of inventions. The difference to the subject matter of claims 6-8, 10-12, 14-21 is the use of the human ELP gene of D8 for diagnostic and medical purposes as described in said claims. The cited prior art does not contain any indication that would prompt the skilled person to use the gene of D8 for such purposes. Said claims, are, therefore formally acknowledged, inventive (see however, paragraph 4).
4. The present application does not provide evidence that the human ELP protein of D8 can be used for methods as described in claims 6-8, 10-12, 14-21. In addition, hyperproliferative diseases associated with the ELP protein of D8, as described in claim

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/IB 03/01257

15, have not been disclosed and are not known in the prior art. **Claims 6-8, 10-12, 14-21** are, therefore, not disclosed, contrary to Art. 5 PCT.



Claims

1. An isolated protein comprising an ENTH domain and having growth inhibiting activity.

5 2. The protein of claim 1 wherein said protein lacks a NPF domain which interacts with Eps15 and lacks a DPW domain which binds to the clathrin adaptor AP2.

10 3. The protein of claim 1 or 2 wherein said protein has an amino acid sequence which is at least 40%, preferably 50%, more preferably 70%, even more preferably 80% and most preferably 90% identical to one of the amino acid sequences set forth in Seq. Id. No. 2, 4 and 5.

15 4. The protein of anyone of claims 1 to 3 wherein said protein has an amino acid sequence which is identical to the amino acid sequence of Seq. Id. No. 2, Seq. Id. No. 4 or Seq. Id. No. 5.

20 5. An isolated nucleic acid encoding a protein of any one of claims 1 to 4, preferably a nucleic acid sequence set forth in Seq. Id. No. 1 or Seq. Id. No. 3.

6. A vector comprising a nucleic acid as defined in claim 5.

25 7. A host cell comprising a vector of claim 6.

8. The host cell of claim 7, wherein said cell is an eukaryotic cell.

30 9. A method for the identification of a hyperproliferative disease, in particular benign and malignant tumors, or a genetic predisposition thereof, which comprises detecting in a body fluid or a tissue sample of a subject a change in the expression level and/or at least one mutation within a nucleic acid sequence encoding an ELP protein or detecting a  
35 rearrangement in the genomic elp locus.

10. The method of claim 9 wherein said mutation is located within the DNA region coding for the

*Replaced by  
Article 34*

ENTH domain, in the 5' untranslated region, in a codon encoding an evolutionary conserved amino acid, in the promoter or in a splicing site.

11. The method of anyone of claims 9-10,  
5 wherein said mutation leads to a non-functional ELP protein, to a reduced protein expression or no protein, or a fusion protein.

12. The method of anyone of claims 9-11,  
wherein said nucleic acid sequence is the nucleic acid  
10 sequence of Seq. Id. No. 1.

13. The method of anyone of claims 9 to 12,  
wherein the disease is lung cancer.

14. The method of anyone of claims 9 to 12,  
wherein the disease is kidney cancer.

15 15. The method of anyone of claims 9 to 12,  
wherein the disease is stomach cancer.

16. A method for the production of an ELP  
protein comprising transformation of suitable host cells  
with a nucleic acid encoding a protein of claim 1 in an  
20 expression construct, cultivation of said cells under  
conditions allowing protein expression of said protein,  
and isolation of the produced proteins.

17. An antibody capable of binding  
specifically to an epitope of a protein of claim 1.

25 18. Use of an antibody of claim 17 in a  
method for the identification of a hyperproliferative  
disease or a genetic predisposition thereof.

19. Use of a nucleic acid of claim 5 for the  
gene therapy of a hyperproliferative disease associated  
30 with ELP proteins.

20. A pharmaceutical composition for the  
treatment of a hyperproliferative disease, in particular  
benign and malignant tumors, comprising a protein of  
anyone of claims 1 to 4 and/or a nucleic acid of claim 5.

35 21. The pharmaceutical composition of claim  
20, wherein the hyperproliferative disease is lung  
cancer.

Replaced by  
Art 34

22. The pharmaceutical composition of claim 20, wherein the hyperproliferative disease is kidney cancer.

23. The pharmaceutical composition of claim 5 20, wherein the hyperproliferative disease is stomach cancer.

24. An oligonucleotide for the down regulation of gene expression which specifically hybridizes to a region of a mRNA encoding an epsin like 10 protein.

25. The oligonucleotide of claim 24, wherein said oligonucleotide comprises chemical modifications.

26. A double stranded RNA (dsRNA) for gene silencing wherein said RNA has a nucleotide sequence 15 which is complementary to an exon region of a gene encoding an ELP protein.

27. The dsRNA of claim 26 which has a length of about 200-2000 base pairs, preferably 700-800 base pairs.

28. The dsRNA of claim 21 which has a length of about 18-25 base pairs, preferably 20-22 base pairs.

29. The dsRNA of claim 26, wherein said epsin like protein is human ELP.

30. Use of the oligonucleotide or dsRNA of 25 anyone of claims 24 to 29 for the therapy of hypoproliferative diseases and/or diseases characterized by incorrect cell differentiation.

*Replaced  
by Art 34*